论文部分内容阅读
本刊8月份刊登了一篇题为“医药产业岂能成为支柱产业”的文章,刊出后引起了广大读者的强烈反响,也引发了关于“医药产业该不该成为支柱产业”的激烈争论。支持者认为,随着我国经济总体实力的提高,医药产业风生水起,产值逐年增加,占GDP的比重越来越大;它同时能够带动相关产业的发展,潜力不可低估,符合我国支柱产业的特征,理所当然要成为支柱产业。反对者则认为,药品是不能等同于普通商品的特殊商品,医药产业直接关系人民的生命健康安全,有其不适合作为支柱产业的特征。如果把医药产业作为支柱产业,必然危害无穷。为此,本期辩论会邀请了部分业内业外人士,围绕“医药产业该不该成为支柱产业”这个话题展开辩论。
In August, we published an article titled “How Can the Pharmaceutical Industry Become a Pillar Industry?”, Which has aroused strong repercussions from readers and also raised questions about whether the “pharmaceutical industry should become a pillar industry ”The heated debate. Proponents argue that with the improvement of China’s overall economic strength, the pharmaceutical industry has become more and more prosperous and its output value has been increasing year by year, accounting for an ever-increasing proportion of GDP. It can also promote the development of related industries and its potential can not be underestimated, which is in line with China’s pillar industries Of the characteristics, of course, to become a pillar industry. Opponents argue that medicine is a special commodity that can not be equated with common commodities. The pharmaceutical industry has a direct bearing on people’s life, health and safety, and is not suitable as a pillar industry characteristic. If the pharmaceutical industry as a pillar industry, inevitably endangering infinity. To this end, this debate will invite part of the industry outsiders, around the “pharmaceutical industry should not become a pillar industry,” this topic debate.